SYT9 and prostate carcinoma: A case–control study of prostate cancer patients receiving androgen deprivation therapy (ADT) uncovered a germline variant signature consisting of three (rs6728684/KIF3C, rs3737336/CDON, rs1045747/IFI30), four (rs6728684/KIF3C, rs1071738/PALLD, rs998754/GABRA1, rs4351800/SYT9), and one (rs4351800/SYT9) miR‐SNPs that were significantly correlated for disease progression, prostate cancer‐specific mortality, and all‐cause mortality, respectively.